Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment
This story is reported by Wiley & Sons. Read what other outlets are saying below, then open the original report for full details.